



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**17 March 2021**

---

## **Bionomics Limited announces Placement to be conducted concurrently with Entitlement Offer**

Bionomics Limited (ASX: BNO) (**Bionomics** or **Company**), a clinical stage biopharmaceutical company, is pleased to announce that it is inviting certain investors who participated in the Company's placement announced on 9 February 2021 and which completed on 2 March 2021 (**February 2021 Placement**), to apply for further new shares, concurrently with the Company's entitlement offer announced on 8 March 2021 (**Entitlement Offer**).

The concurrent placement is being offered only to those investors who participated in the strongly over-subscribed February 2021 Placement but are unable to participate in the Entitlement Offer due to having a registered address outside of Australia or New Zealand.

The offer under the concurrent placement is to be made on substantially the same terms as the Entitlement Offer, being on a 1:6 pro rata basis, with an opportunity to apply for further shares up to 100% of the invitee's 1:6 for pro rata allocation. The invitation to apply for shares under the concurrent placement is not transferrable.

If a subscriber applies for additional shares, and there is a scale back of oversubscriptions under the Entitlement Offer, then the subscriber's application for additional shares will be scaled back in the same way, so that they are treated in the same manner as shareholders who apply under the Entitlement Offer.

Up to approximately 21,138,367 shares will be issued under the concurrent placement to raise up to A\$3,065,063, in addition to the approximately A\$20,000,000 to be raised in the Entitlement Offer.

The shares to be issued under the concurrent placement will either be allocated from the shortfall under the Entitlement Offer, should there be a shortfall, or otherwise under the Company's expanded placement capacity following the completion of the Entitlement Offer. In either case, it is expected that the shares will be issued on the same date as shares issued under the Entitlement Offer (currently expected to be 8 April 2021).

*This announcement is given under section 708AA(12) of the Corporations Act 2001 (Cth) as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84.*

This announcement was approved by Dr Errol De Souza, Executive Chairman on behalf of the Board of Directors of Bionomics.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalglish St,  
Thebarton, South Australia  
+61 8 8354 6100  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

**About Bionomics Limited**

Bionomics Limited (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

**Important information**

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which such an offer would be illegal. Neither the entitlements nor the Shares to be offered and sold under the concurrent placement or the Entitlement Offer have been, or will be, registered under the U.S. Securities Act of 1933 (U.S. Securities Act) or the securities laws of any state or other jurisdiction of the United States. Accordingly, the offers or entitlements may not be exercised or taken up by, and the shares may not be offered or sold, directly or indirectly, to, persons in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities law of any state or other jurisdiction of the United States.